Leading UK humanitarian aid charity, Human Appeal, today announces the addition of an e-greeting card feature to its website, which will allow the public the opportunity to send family and friends ...
Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary ...
The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an ...
Paris, le 24 décembre 2025. La Food and Drug Administration (FDA) américaine a émis une lettre de réponse complète (Complete Response Letter) pour la demande d'autorisation de mise sur le marché du to ...
Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline ...
Dynavax’s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...
Authorization for the Reverse Split was approved by the Company’s stockholders at SeaStar Medical’s 2025 Special Meeting of Stockholders held on December 18, 2025. The objective of the Reverse Split ...
Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., ...
“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced ...
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and ...
The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback